Skip to content

Tissue Characterization and Primary Percutaneous Coronary Intervention Guidance Using Intravascular Ultrasound

Tissue Characterization and Primary Percutaneous Coronary Intervention Guidance Using Intravascular Ultrasound

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05007535
Acronym
SPECTRUM
Enrollment
200
Registered
2021-08-16
Start date
2020-11-10
Completion date
2023-02-02
Last updated
2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Coronary Artery Disease, Intravascular Ultrasound, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Thrombus

Keywords

Invasive Coronary Imaging

Brief summary

This prospective, single arm, observational cohort study is designed to assess the safety and efficacy of (high-definition) intravascular ultrasound (HD-IVUS) as guidance for primary percutaneous coronary intervention (PCI) and to assess culprit lesion plaque characteristics and thrombus morphology in patients with ST-elevation myocardial infarction (STEMI). Objectives: * To assess clinical outcomes after IVUS-guided primary PCI in STEMI patients. * To assess IVUS-guided optimization in STEMI patients. * To assess culprit lesion plaque characteristics in STEMI patients with HD-IVUS. * To assess and quantify thrombus in STEMI patients with HD-IVUS. * To explore HD-IVUS derived predictors for clinically relevant aspiration thrombectomy.

Detailed description

The SPECTRUM study is an investigator-initiated, single-center, prospective, single arm, observational cohort study investigating the safety and efficacy of (HD)-IVUS as guidance for primary PCI in 200 patients with STEMI. This study enables the assessment of culprit lesion plaque characteristics and thrombus morphology with a 40-60 MHz HD-IVUS catheter. All study patients will have a protocolized pre-intervention IVUS pullback directly after recanalization (so before any lesion preparation, i.e. balloon dilatation, aspiration thrombectomy or stent placement) and a post-intervention IVUS pullback. Subsequently, if IVUS-guided optimization is performed, a final pullback is highly recommended and considered as the post-optimization IVUS pullback. The primary study outcomes are target vessel failure at 12 months and incidence of IVUS-guided optimization. More information on outcome measures is provided in the section below.

Interventions

None listed

Sponsors

Acist Medical Systems
CollaboratorINDUSTRY
MicroPort CRM
CollaboratorINDUSTRY
Erasmus Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Native coronary artery culprit lesion, angiographically * Culprit vessel reference diameter ≥ 2.25 mm, angiographically

Exclusion criteria

* Cardiogenic shock * Presentation \> 12 hours after symptom onset

Design outcomes

Primary

MeasureTime frameDescription
Target Vessel Failure (TVF)12 MonthsA composite of cardiac death, target vessel myocardial infarction and clinically driven target vessel revascularization
IVUS-guided optimizationProceduralIncidence of IVUS-guided additional balloon dilatation or stent placement after angiographically successful PCI

Secondary

MeasureTime frameDescription
Individual Components of TVF and MACE30 DaysIndividual components of the composite endpoints
Major Intraprocedural ComplicationsProceduralIncluding type C-F dissections, perforations, slow flow or no-reflow, major side branch occlusion (\> 2 mm)
TVF30 DaysA composite of cardiac death, target vessel myocardial infarction and clinically driven target vessel revascularization
IVUS endpoints (continuous)ProceduralAt least the following continuous variables will be assessed for the first 100 patients with sufficient HD-IVUS pullbacks: * Minimal lumen area * Thrombus containing frames * Thrombus maximum angle * Minimal stent area Structured analysis of the HD-IVUS pullbacks will be performed with dedicated invasive imaging analysis software.
IVUS endpoints (categorical)ProceduralAt least the following categorical variables will be assessed for the first 100 patients with sufficient HD-IVUS pullbacks: * Plaque rupture * Convex calcium (nodule) * Thrombus type * Plaque type * Thrombus protrusion * Underexpansion * Edge dissection * Hematoma * High plaque burden at stent edges * Residual focal lesion * Malapposition Structured analysis of the HD-IVUS pullbacks will be performed with dedicated invasive imaging analysis software.
Angiographic EndpointsProceduralIncluding final TIMI flow and final myocardial blush grade
Major Adverse Cardiovascular Events (MACE)30 DaysA composite of all-cause mortality, any myocardial infarction and repeat revascularization

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026